Biologic and biosimilar RA drugs market seen reaching $20.53B by 2030
The biologic and biosimilar rheumatoid arthritis drugs market is projected to grow from $14.57 billion in 2025 to $15.55 billion in 2026, according to The Business Research Company. The report points to rising RA cases, higher healthcare spending and faster biosimilar adoption as key forces behind growth through 2030.
Why it matters: - The biologic and biosimilar rheumatoid arthritis drugs market is expanding as more patients need targeted RA treatments and payers look for lower-cost options. - The shift matters because biologics and biosimilars can offer more precise disease control than traditional therapies. - Wider biosimilar use could ease pressure on healthcare budgets as specialty drug spending rises.
What happened: - The Business Research Company released its Biologic and Biosimilar RA Drugs Global Market Report 2026 on Nov. 20, 2026. - The report estimates the market will grow from $14.57 billion in 2025 to $15.55 billion in 2026. - The report forecasts the market will reach $20.53 billion by 2030. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report is available through the full report. - A free sample is available through the sample report.
The details: - The market is projected to post a 6.8% CAGR from 2025 to 2026. - The report forecasts a 7.2% CAGR through 2030. - Growth over the past period has been driven by rising rheumatoid arthritis cases, limited treatment alternatives, higher investment in biologics research, rising healthcare expenditures and patent expirations for key biologic drugs. - The report says wider biosimilar acceptance, drug-delivery innovation, expanded production capacity, supportive regulation and precision medicine will drive future growth. - The report highlights emerging trends in personalized biologic treatments, faster biosimilar adoption, advanced delivery systems, global regulatory alignment and lower-cost RA therapies. - Biologics and biosimilars are medicines derived from living organisms such as cells and microorganisms. - Biosimilars closely resemble an already approved biologic product. - Both drug types are used to manage rheumatoid arthritis by targeting disease mechanisms more precisely than traditional treatments. - North America held the largest market share in 2025. - Asia-Pacific is projected to grow the fastest during the forecast period. - The 2026 report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and key technology and future trend analysis.
Between the lines: - The report frames RA drug growth as a mix of clinical need and pricing pressure, with biosimilars positioned as the main lever for broader access. - The emphasis on regulation, delivery tech and manufacturing capacity suggests competition will hinge on both scientific differentiation and commercial scale. - Rising healthcare spending supports the market now, but it also increases demand for therapies that can improve outcomes without worsening cost growth.
What's next: - The market’s next phase likely depends on how quickly biosimilars gain acceptance in major regions. - Regulatory clarity and expanded manufacturing capacity could speed adoption through 2030. - Cost reduction efforts are expected to remain a major theme as health systems manage chronic autoimmune disease spending. - Further regional growth in Asia-Pacific could narrow North America’s lead over time.
The bottom line: - The RA biologics and biosimilars market is on track for steady double-digit-dollar growth, with biosimilar adoption and healthcare cost control shaping the next five years.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Asia News Digest
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.